Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Baron Health Care Fund Neal Kaufman | “Xenon Pharmaceuticals Inc. ($XENE) is a clinical-stage biopharmaceutical developer focused on novel ion channel therapies for neurological disorders. The manager adopted a definitive bearish stance, completely exiting the Fund's position following severe clinical trial safety signals. Economically, Xenon's enterprise valuation was heavily anchored in the peak commercial sales potential of its lead asset, azetukalner, across multiple central nervous system indications. When Phase 3 depression trials revealed severe neuropsychiatric adverse events - such as ataxia and psychosis - the asset's risk-adjusted net present value severely deteriorated. The adverse safety profile threatened to impose significant negative regulatory friction across its entire developmental platform, severely impairing projected returns on research capital. Key risks that precipitated the exit include the potential for restrictive black-box FDA labeling, burdensome Risk Evaluation and Mitigation Strategies (REMS), or delayed approval for its lead epilepsy indication. No positive near-term catalysts were deemed sufficient to offset these heightened regulatory and commercial liabilities.” | BEAR | Q3 2026 Oct 14, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.